Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-06-21 | HEB | Hemispherx Biopharma Inc | Appelrouth Stewart | Dir | P - Purchase | $4.03 | +9,677 | 26,708 | +57% | +$38,998 | ||||||
2019-06-20 | CHRS | Coherus Biosciences, Inc. | Healy James | Dir | S - Sale | $21.37 | -317,130 | 2,293,313 | -12% | -$6,777,068 | ||||||
| D | 2019-06-20 | RUBY | Rubius Therapeutics, Inc. | Carpenter Christopher L. | Chief Medical Officer | S - Sale+OE | $13.93 | -243 | 34,843 | -1% | -$3,386 | |||||
2019-06-21 | HEB | Hemispherx Biopharma Inc | Springate Wayne S | SVP of Operations | P - Purchase | $4.03 | +5,211 | 8,672 | +151% | +$21,000 | ||||||
2019-06-21 | HEB | Hemispherx Biopharma Inc | Mitchell William M | Dir | P - Purchase | $4.03 | +9,677 | 20,838 | +87% | +$38,998 | ||||||
2019-06-20 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $9.00 | +300 | 84,527 | 0% | +$2,700 | ||||||
2019-06-20 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $13.00 | -39,433 | 6,980 | -85% | -$512,629 | ||||||
| D | 2019-06-19 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $52.54 | -15,000 | 246,000 | -6% | -$788,088 | |||||
2019-06-21 | HEB | Hemispherx Biopharma Inc | Equels Thomas K. | Exec. Vice COB, CEO, Pres | P - Purchase | $4.03 | +29,404 | 1,393,611 | +2% | +$118,498 | ||||||
| D | 2019-06-18 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $87.82 | -2,100 | 141,976 | -1% | -$184,417 | |||||
2019-06-18 | GILD | Gilead Sciences Inc | Pletcher Brett A | EVP, GC, Corp Sec | S - Sale | $68.75 | -5,816 | 27,198 | -18% | -$399,850 | ||||||
| D | 2019-06-18 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Strategy Officer | S - Sale+OE | $126.12 | -100 | 40,921 | 0% | -$12,612 | |||||
| D | 2019-06-18 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $52.99 | -5,000 | 3,006 | -62% | -$264,965 | |||||
| DM | 2019-06-18 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale+OE | $19.85 | -6,826 | 11,513 | -37% | -$135,514 | |||||
| DM | 2019-06-17 | RUBY | Rubius Therapeutics, Inc. | Carpenter Christopher L. | Chief Medical Officer | S - Sale+OE | $14.02 | -47,757 | 34,843 | -58% | -$669,694 | |||||
| M | 2019-06-17 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $10.59 | +800 | 84,227 | +1% | +$8,468 | |||||
| AD | 2019-05-23 | RGEN | Repligen Corp | Cooper Glenn L Md | Dir | S - Sale+OE | $66.94 | -5,000 | 59,709 | -8% | -$334,715 | |||||
| D | 2019-06-17 | RGEN | Repligen Corp | Dawes Karen A | Dir | S - Sale+OE | $77.35 | -1,295 | 117,034 | -1% | -$100,168 | |||||
2019-06-17 | SGEN | Seattle Genetics Inc /wa | Dansey Roger D | Chief Medical Officer | S - Sale | $68.60 | -5,416 | 77,593 | -7% | -$371,538 | ||||||
| D | 2019-06-17 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $46.00 | -20,000 | 165,801 | -11% | -$920,000 | |||||
2019-06-14 | XLRN | Acceleron Pharma Inc | Zakrzewski Joseph S | Dir | P - Purchase | $38.05 | +5,000 | 12,750 | +65% | +$190,250 | ||||||
| D | 2019-06-13 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $82.62 | -17,268 | 141,976 | -11% | -$1,426,628 | |||||
| D | 2019-06-12 | TECH | Bio-Techne Corp | Eansor Norman David | SVP - Novus Biologicals | S - Sale+OE | $215.00 | -3,117 | 0 | -100% | -$670,155 | |||||
2019-05-10 | CRTX | Cortexyme, Inc. | Epiq Capital Group, LLC | IA/Managing Member 10% owner | P - Purchase | $26.98 | +8,600 | 8,476,058 | 0% | +$232,056 | ||||||
| M | 2019-06-11 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $9.95 | +400 | 83,428 | 0% | +$3,979 | |||||
2019-06-11 | PTE | Polarityte, Inc. | Swanson Edward Winslow | Chief Trans. Med. Officer | P - Purchase | $5.66 | +2,000 | 37,661 | +6% | +$11,315 | ||||||
2019-06-10 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $18.77 | -7,500 | 648,327 | -1% | -$140,775 | ||||||
| D | 2019-06-10 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $18.78 | -17,500 | 162,798 | -10% | -$328,653 | |||||
| D | 2019-06-10 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $69.05 | -20,148 | 746,294 | -3% | -$1,391,175 | |||||
2019-06-10 | PTE | Polarityte, Inc. | Gorlin Steve | Dir | S - Sale | $5.94 | -53,700 | 1,300 | -98% | -$318,978 | ||||||
| D | 2019-06-10 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Strategy Officer | S - Sale+OE | $125.44 | -1,400 | 40,921 | -3% | -$175,619 | |||||
2019-06-10 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $45.00 | -50,000 | 898,007 | -5% | -$2,250,000 | ||||||
| D | 2019-06-10 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale+OE | $15.62 | -17,500 | 122,672 | -12% | -$273,373 | |||||
| D | 2019-06-10 | EVFM | Evofem Biosciences, Inc. | Pdl Biopharma, Inc. | 10% | P - Purchase | $4.50 | +6,666,667 | 13,333,334 | +100% | +$30,000,002 | |||||
| D | 2019-06-06 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $122.64 | -5,060 | 31,616 | -14% | -$620,539 | |||||
2019-06-07 | MCTC | McTc Holdings, Inc. | Lauderdale Holdings, LLC | Pres, 10% | S - Sale | $0.00 | -130,000,000 | 0 | -100% | -$325,000 | ||||||
| M | 2019-06-06 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $11.14 | +235 | 83,028 | 0% | +$2,619 | |||||
2019-06-05 | NSTG | Nanostring Technologies Inc | Ghesquiere David W. | SVP, Corporate, Business Dev | S - Sale | $29.41 | -6,954 | 44,868 | -13% | -$204,493 | ||||||
2019-06-06 | ADMA | Adma Biologics, Inc. | Biotest Divestiture Trust | 10% | S - Sale | $3.75 | -5,813,954 | 4,295,580 | -58% | -$21,802,328 | ||||||
2019-06-05 | BLUE | Bluebird Bio, Inc. | Wentworth Kory James | Principal Accounting Officer | S - Sale | $127.60 | -61 | 6,846 | -1% | -$7,784 | ||||||
| D | 2019-06-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $128.60 | -1,800 | 31,092 | -5% | -$231,488 | |||||
2019-06-05 | APTO | Aptose Biosciences Inc. | Chow Gregory K. | SVP, CFO | P - Purchase | $1.84 | +7,500 | 134,514 | +6% | +$13,815 | ||||||
| D | 2019-06-04 | TECH | Bio-Techne Corp | Higgins John L | Dir | S - Sale+OE | $203.67 | -5,000 | 3,526 | -59% | -$1,018,346 | |||||
2019-06-05 | PTE | Polarityte, Inc. | Swanson Edward Winslow | Chief Trans Med Officer | P - Purchase | $5.68 | +2,000 | 35,661 | +6% | +$11,367 | ||||||
2019-06-05 | PTE | Polarityte, Inc. | Seaburg David B | Pres of Corp Development | P - Purchase | $5.93 | +35,000 | 100,000 | +54% | +$207,550 | ||||||
2019-06-05 | PTE | Polarityte, Inc. | Mann Paul Elliot | CFO | P - Purchase | $5.33 | +35,000 | 156,247 | +29% | +$186,519 | ||||||
2019-06-05 | PTE | Polarityte, Inc. | Cohen Peter A | Dir | P - Purchase | $5.63 | +15,000 | 72,500 | +26% | +$84,471 | ||||||
| M | 2019-06-04 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.02 | +2,000 | 745,142 | 0% | +$2,039 | |||||
| D | 2019-06-05 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $175.68 | -2,000 | 14,219 | -12% | -$351,360 | |||||
| D | 2019-06-03 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $85.51 | -3,435 | 141,976 | -2% | -$293,719 | |||||
| D | 2019-06-03 | ALLO | Allogene Therapeutics, Inc. | Moore Alison | Chief Technical Officer | S - Sale+OE | $26.76 | -48,828 | 37,557 | -57% | -$1,306,774 | |||||
2019-06-03 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $19.07 | -18,333 | 2,573,476 | -1% | -$349,610 | ||||||
2019-06-03 | INMB | Inmune Bio, Inc. | Powers Linda F | 10% | P - Purchase | $6.00 | +10,000 | 1,130,000 | +1% | +$60,000 | ||||||
| D | 2019-05-31 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $65.94 | -8,000 | 177,329 | -4% | -$527,485 | |||||
2019-06-03 | INMB | Inmune Bio, Inc. | Juda Scott | Dir | P - Purchase | $6.00 | +10,000 | 22,500 | +80% | +$60,000 | ||||||
2019-06-03 | INMB | Inmune Bio, Inc. | Moss David J | CFO, Treasurer, Secretary, 10% | P - Purchase | $6.00 | +10,000 | 1,220,417 | +1% | +$60,000 | ||||||
2019-06-03 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $6.00 | +10,000 | 1,536,933 | +1% | +$60,000 | ||||||
2019-05-30 | HSKA | Heska Corp | Humphrey Scott | Dir | P - Purchase | $73.79 | +1,000 | 3,062 | +48% | +$73,790 | ||||||
| D | 2019-05-31 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $85.02 | -19,297 | 141,976 | -12% | -$1,640,581 | |||||
2019-05-30 | CHRS | Coherus Biosciences, Inc. | Lanfear Dennis M | Pres, CEO | S - Sale | $19.49 | -32,398 | 1,496,166 | -2% | -$631,282 | ||||||
| M | 2019-05-29 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $23.09 | -5,850 | 622,930 | -1% | -$135,089 | |||||
| D | 2019-05-28 | RGNX | Regenxbio Inc. | Simpson Curran | SVP, Product Development, CTO | S - Sale+OE | $50.00 | -18,000 | 39,500 | -31% | -$900,000 | |||||
2019-05-28 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.28 | +200 | 743,142 | 0% | +$256 | ||||||
| D | 2019-05-24 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $80.03 | -17,486 | 141,976 | -11% | -$1,399,434 | |||||
| D | 2019-05-24 | TECH | Bio-Techne Corp | Furlow Brenda S. | SVP - GC | S - Sale+OE | $200.00 | -5,400 | 2,189 | -71% | -$1,080,000 | |||||
2019-05-23 | RGEN | Repligen Corp | Cooper Glenn L Md | Dir | S - Sale | $66.94 | -5,000 | 35,709 | -12% | -$334,715 | ||||||
2019-05-22 | CHRS | Coherus Biosciences, Inc. | Healy James | Dir | S - Sale | $20.69 | -257,870 | 2,610,443 | -9% | -$5,335,330 | ||||||
2019-05-22 | BCRX | Biocryst Pharmaceuticals Inc | Aselage Steve | Dir | P - Purchase | $3.57 | +3,000 | 5,000 | +150% | +$10,710 | ||||||
| D | 2019-05-22 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $80.03 | -1,300 | 141,976 | -1% | -$104,037 | |||||
| D | 2019-05-21 | ADMA | Adma Biologics, Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $4.00 | +4,000,000 | 11,521,102 | +53% | +$16,000,000 | |||||
| D | 2019-05-20 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $42.99 | -15,000 | 246,000 | -6% | -$644,866 | |||||
2019-05-21 | CVM | Cel Sci Corp | Young Peter R | Dir | P - Purchase | $5.00 | +2,000 | 21,091 | +10% | +$10,000 | ||||||
2019-05-17 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $4.00 | +12,000 | 179,857 | +7% | +$48,000 | ||||||
2019-05-17 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | P - Purchase | $4.00 | +25,000 | 51,000 | +96% | +$100,000 | ||||||
2019-05-17 | ADMA | Adma Biologics, Inc. | Mond James | EVP, CSO, CMO | P - Purchase | $4.00 | +4,500 | 17,889 | +34% | +$18,000 | ||||||
2019-05-17 | ADMA | Adma Biologics, Inc. | Lenz Brian | EVP, CFO | P - Purchase | $4.00 | +5,000 | 25,000 | +25% | +$20,000 | ||||||
2019-05-17 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | P - Purchase | $4.00 | +30,000 | 1,439,785 | +2% | +$120,000 | ||||||
| A | 2019-05-02 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $10.75 | +11,100 | 1,526,933 | +1% | +$119,325 | |||||
| A | 2019-05-06 | INMB | Inmune Bio, Inc. | Moss David J | CFO, Treasurer, Secretary, 10% | P - Purchase | $10.71 | +5,000 | 1,210,417 | 0% | +$53,550 | |||||
| M | 2019-05-16 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.15 | +2,100 | 742,942 | 0% | +$2,422 | |||||
| D | 2019-05-16 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $80.13 | -66,667 | 141,976 | -32% | -$5,341,893 | |||||
| D | 2019-05-17 | LIFE | Atyr Pharma Inc | Krueger Nancy | GC | S - Sale+OE | $0.45 | -4,651 | 25,348 | -16% | -$2,093 | |||||
| DM | 2019-05-16 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $7.65 | -9,750 | 125,176 | -7% | -$74,595 | |||||
| D | 2019-05-16 | FATE | Fate Therapeutics Inc | Wolchko J Scott | Pres, CEO | S - Sale+OE | $19.37 | -14,335 | 374,881 | -4% | -$277,684 | |||||
| D | 2019-05-15 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | EVP, CFO | S - Sale+OE | $10.00 | -5,000 | 25,512 | -16% | -$50,000 | |||||
| DM | 2019-05-14 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $7.81 | -11,750 | 130,176 | -8% | -$91,710 | |||||
2019-05-14 | HARP | Harpoon Therapeutics, Inc. | McMahon Gerald Phd | Pres, CEO | P - Purchase | $10.16 | +1,000 | 3,000 | +50% | +$10,157 | ||||||
2019-05-13 | NBIX | Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | CHIEF RESEARCH OFFICER | S - Sale | $75.44 | -1,657 | 118,408 | -1% | -$125,007 | ||||||
| D | 2019-05-13 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $75.51 | -34,547 | 141,976 | -20% | -$2,608,813 | |||||
| D | 2019-05-14 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $13.72 | -2,778 | 507,996 | -1% | -$38,114 | |||||
| D | 2019-05-13 | BOLD | Audentes Therapeutics, Inc. | Prasad Suyash | SVP, Chief Med Officer | S - Sale+OE | $36.98 | -10,000 | 18,236 | -35% | -$369,798 | |||||
| M | 2019-05-13 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $24.61 | -7,800 | 628,780 | -1% | -$191,973 | |||||
2019-05-13 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $26.59 | -50,000 | 26,530 | -65% | -$1,329,421 | ||||||
| D | 2019-05-13 | AXLA | Axcella Health Inc. | Flagship Ventures Fund IV General Partner LLC | 10% | P - Purchase | $20.00 | +500,000 | 3,700,463 | +16% | +$10,000,000 | |||||
2019-05-14 | ALLO | Allogene Therapeutics, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | 10% | S - Sale | $29.38 | -1,918,755 | 21,216,306 | -8% | -$56,373,022 | ||||||
2019-05-10 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $14.00 | -114 | 46,413 | 0% | -$1,596 | ||||||
2019-05-10 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale | $14.13 | -1,772 | 504,602 | 0% | -$25,038 | ||||||
2019-05-10 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $14.00 | -354 | 69,085 | -1% | -$4,956 | ||||||
| D | 2019-05-10 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale+OE | $14.00 | -354 | 99,518 | 0% | -$4,956 | |||||
2019-05-10 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $14.00 | -354 | 4,871 | -7% | -$4,956 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |